So just how can anybody question the advantages of a medication? To begin with, many investigators harbor doubts concerning the necessity to push down cholesterol levels at the first location. Those doubts were fortified on Jan. 14, when Merck and Schering-Plough (SGP) showed results of a trial where popular cholesterol-lowering medication, a station that has been reinforced by a different, Zetia, that works by another mechanism. The mix did succeed in shoving patients’ cholesterol farther than with the statin . But with two decades of therapy, the reductions attracted no health advantage. The critical thing is currently hiding in plain sight in Pfizer Lipitor’s paper advertisement. Read the kind. Do some very simple math.
The figures in that sentence imply that for every 100 men and women 3 1/3 decades in the trial, which lasted, three individuals on placebos and 2 individuals on Lipitor had heart attacks. The difference attributed to this medication? One heart attack per 100 individuals. To save 1 man a heart attack, 100 individuals needed to choose Lipitor for over three data pengeluaran togel sgp decades. No measurable benefit was achieved by the 99. Compare this with, say, the current normal antibiotic treatment to eliminate ulcer-causing H. pylori gut bacteria. Give the medication to 11 individuals, and 10 will be treated. There is A very low NNT the kind of response many individuals expect. When Wright and many others describe to patients with no previous heart disease that just 1 in 100 is most very likely to profit from taking statins many are amazed.
Many, such as Winn, decide to go out. Plus, there are many reasons to consider the general benefit for most patients is much less than that which the NNT rating of 100 indicates. That NNT was discovered within a trial together with patients with risk factors, including hypertension or smoking. By comparison, the big clinical trial funded by the authorities, as opposed to employers, found no significant advantage. And since clinical trials suffer from possible biases, consequences promising modest benefits are almost always uncertain, states Dr. Nortin M. Hadlea professor of medicine a longtime drug industry critic. Several recent documents peg the NNT for statins in up and 250 for sufferers, even should they choose it .